SRC and lung adenocarcinoma: In sum, inactivated c-Src by dasatinib sealed the phosphorylated tyrosine 1068, 1086, and 1145 of EGFR to inhibit the survival pathway to sensitize EGFR-mutant lung adenocarcinoma to TKI.